The Indian group Biocon Biologics, world leader in biosimilar medicines, announces a new stage in its international expansion with the construction of a production site in Casablanca. This project, estimated at more than 100 million dirhams, marks a significant step forward in the group’s strategy aimed at meeting the growing demand for innovative treatments for serious illnesses such as cancer, diabetes and autoimmune diseases.
Since its arrival in Morocco less than two years ago, Biocon Biologics is now undergoing a major transformation. After modest commercial activity, with a turnover of 4 million dirhams in 2024, the Moroccan subsidiary is preparing to become a key player in the local pharmaceutical sector. The future factory, planned in the Casablanca region, will focus on the production of biosimilar drugs with high added value, intended mainly for the Moroccan market.
These treatments, derived from living organisms, represent an essential alternative to traditional medicines, offering accessible and innovative solutions for serious pathologies. This initiative also reflects Biocon Biologics’ commitment to making healthcare more affordable and accessible to Moroccan patients.
Founded in 1978 in Bengaluru, India, Biocon Biologics has established itself as a key player in the development of biosimilars. With more than 20 products in the final phase of development and investments exceeding a billion dollars in research & development over two decades, the group positions itself as a pioneer in therapeutic innovation.
The planned investment in Morocco demonstrates the group’s ambition to expand its industrial footprint while supporting the growth of the local pharmaceutical industry. This production site is part of a broader vision aimed at making Morocco a regional hub for the pharmaceutical industry.
-In addition to strengthening local drug production capacities, this project will help boost the Moroccan economy by creating jobs and attracting investments in the health sector. The diversification of Biocon Biologics’ activities in Morocco has already been demonstrated by the expansion of the corporate purpose of its subsidiary to include the pharmaceutical establishment activity.
An initial investment of 5 million dirhams has been allocated to launch this project, which represents a strategic opportunity for the Kingdom to consolidate its role as a regional platform for innovation and healthcare.
The entry into service of this industrial site is planned in the coming years. It will not only boost Biocon Biologics Morocco’s revenues, but also effectively meet the needs of Moroccan patients by offering locally manufactured medicines. This project also strengthens Morocco’s efforts to promote innovation, attract foreign investment, and improve access to care for its population.
By consolidating its presence in Morocco, Biocon Biologics confirms its commitment to global therapeutic innovation while playing a key role in the development of the African pharmaceutical industry.
Related News :